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Abstract
Background: Synaptic dysfunction is one of the pathological characteristics of Alzheimer's disease (AD), which is
directly related to the progressive decline of cognitive function. CaMKII and CaN have been found to play important
roles in memory processes and synaptic transmission. So present study aimed to elucidate relationships between
CaMKII, CaN and cognitive decline in APPV717I mice, and to reveal whether the cognitive improving effects of GAPT is
conducted through rebalance CaMKII and CaN.
Methods: Three-month-old-male APPV717I mice were randomly divided into ten groups (n = 12 per group) and
received intragastrically administrated vehicle, donepezil or different doses of herbal formula GAPT for 8 or 4 months.
Three-month-old male C57BL/6 J mice was set as vehicle control.
Results: Immunohistochemistry analysis showed that there were CaMKII expression decrease in the CA1 region of
APPV717I transgenic mice, while the CaMKII expression of donepezil or GAPT treated transgenic mice were all increased.
And there were CaN expression increase in the brain cortex of APPV717I transgenic mice, while there were decrease of
CaN expression in donepezil or GAPT treated transgenic group. Western blot analysis showed the similar expression
pattern without significant difference.
Conclusion: GAPT extract have showed effectiveness in activating the expression of CaMKII and inhibiting the expression
of CaN either before or after the formation of amyloid plaques in the brain of APPV717I transgenic mice, which may in
certain way alleviated neuron synaptic dysfunction in AD.
* Correspondence: jztian@hotmail.com
†Equal contributors
1The 3rd Department of Neurology, Dongzhimen Hospital, Beijing University
of Chinese Medicine, Beijing 100700, China
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Shi et al. BMC Complementary and Alternative Medicine  (2016) 16:159 
DOI 10.1186/s12906-016-1144-7
Background
Dementia is estimated to affect as high as 24 million
worldwide, and is predicted to double every 20 years
through to 2040 [1]. As the leading cause of dementia,
Alzheimer disease (AD) is clinically characterized by
progressive decline in cognitive function, and patho-
logically characterized by neurofibrillary tangles, senile
plaques and synaptic dysfunction. There are increasing
researches on the correlation between synaptic loss and
AD since the relationship was established initially [2].
Synapses is considered to be the earliest site of AD
pathological change, and the rate of synaptic loss is dir-
ectly related to the severity of the disease [3, 4]. While,
synaptic transmission, with underlying phenomena like
long term potentiation (LTP), has been proved to be a
cellular model of learning process [5–8]. Among the
molecules implicated in synaptic transmission, Ca2+/cal-
modulin (CaM)-dependent protein kinase II (CaMKII)
and Ca2+/Calmodulin-dependent protein phosphatase
2B (calcineurin, CaN) have been found to play important
roles in memory processes and neuronal degeneration
[9–16]. CaMKII, a ubiquitous serine/threonine protein
kinase, regulates biosynthesis & exocytosis of neuro-
transmitters,synaptic plasticity and many other cellu-
lar functions [9, 11, 12, 16–18]. It is highly expressed
in the brain, especially in the hippocampal formation
[19–22], with the characters of autophosphorylation
and converting itself from the Ca2+-dependent form
to the Ca2+-independent form [23]. And such in-
creased autophosphorylation is essential for the long-
lasting increase in synaptic efficacy following long-term
potentiation (LTP) in the hippocampus [24]. On one hand,
Genetic CaMKII gene disruption or CaMKII inhibitors
blocking LTP were found in vivo or in vitro studies
[25–27]. On the other hand, viral vector mediated ex-
pression of active CaMKII or active form of CaMKII
injection increases α-amino-3-hydroxy-5-methyl-4-iso-
xazolepropionic acid receptor (AMPAR)-mediated
synaptic transmission and occludes further induction
of LTP [28–30].
Calcineurin (CaN), also known as protein phosphatase
2B (PP2B), is a calmodulin-dependent serine/threonine
phosphatase physiologically activated by Ca2+. It is also
highly expressed in the central nervous system [31] and
responsible for the dephosphorylation of p-CaMKII.
CaN is composed of a catalytic subunit (calcineurin A)
and a tightly bound regulatory subunit (calcineurin B)
[14, 15]. It has been intensely studied as a potential
modulator of both memory processes and neuronal de-
generation. However, there are still controversies about
the relationship between CaN and cognitive decline.
From one aspect, activation of CaN in aged rats is
related with cognitive decline [32] and its inhibition
improves memory performance in some normal aging
rodents, as well as in some APP over expressing AD
models [33–36]. From another aspect, CaN activity has
been reported being reduced in the cortex of AD
patients [37, 38]. Interestingly, recent researches have
revealed the details behind the relationship between
CaN and AD. There are evidences to suggest that Aβ
induces different changes of CaN expression in neurons
and astrocytes [39]. Its catalytic subunit, CaN A, is
proteolytically activated in AD cortex by the degradation
of an autoinhibitory domain [40], which is expressed in
reactive astrocytes surrounding senile plaques [41]. It
has been proposed that amyloid beta (Aβ)-induced
perturbation of LTP potentially involves enhanced CaN
activity, and the latter creates an imbalance between
CaN and PKA activity, causing over activation of protein
phosphatase 1 (PP1). While, PP1 acts as a regulator of
the phosphorylation of CaMKII, and therefore, ultim-
ately influences dephosphorylation of CaMKII (reviewed
by [42]).
However, there are still not very clear on the relation-
ships between CaMKII, CaN and cognitive decline in
APPV717I mice. So this study aimed to elucidate their
relationships and reveal whether the cognitive improving
effects of GAPT is conducted through rebalance CaM-
KII and CaN.
GAPT, also called as GEPT in our previous papers, is
a combination of herbal extracts, including eight active
components pro rata of Ginsenoside from ginseng 4.4 %,
Cistanche 17.3 %, Radix Rehmanniae 17.3 %, Polygala
tenuifolia 13 %, Acorus tatarinowii 13 %, Radix Curcumae
13 %, Poria cocos 13 %, Salvia officinalis 9 % [43].
Owing to the kidney deficiency and phlegm turbid
pathogenesis of AD, GAPT was made according to the
therapeutic principle of reinforcing kidney Yang and
reducing phlegm. That is Ginseng, Cistanche, Radix
Rehmanniae and Poria cocos reinforcing kidney; while
Acorus tatarinowii, Radix Curcumae, Salvia officinalis
and Polygala tenuifolia reducing phlegm turbid. Previous
studies indicated that GAPT extract can markedly
improves learning and memory of AD rat models made
from hippocampal injection of Aβ1-42 peptide or intra-
venous injection of Aβ1-40 peptide [44], and reduces the
level of Aβ in APPV717I transgenic mice via inhibiting
γ-secretase (presenilin-1) and promoting insulin degrad-
ing enzyme and neprilysin [43]. Moreover, GAPT also
showed significant improvement on cognitive function
in patients with amnestic mild cognitive impairment
(aMCI), an intermediate stage between normal aging
and the more serious decline of AD, consistently across
different cognitive scales in a 24-week preliminary clin-
ical study [45]. While, the mechanisms behind synaptic
protection effects of GAPT is still not well understood.
This study therefore aimed to reveal the influences of
GAPT in the balance of CaMKII and CaN.
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Methods
Drugs preparation
GAPT, a combination of herbal extracts, was provided
by Henan Wanxi Pharmaceutical Company Limited
(Batch No: 20010923) and hydrochloric acid donepezil
tablets were provided by Eisai (China) Pharmaceutical
Company Limited (Batch No: 090508A). GAPT was
dissolved in 0.5 % Carboxymethyl cellulose (CMC) at
concentration of 30 mg/ml. Donepezil tablets were
crashed and also dissolved in 0.5 % CMC at concentra-
tion of 0.092 mg/ml.
Animal and administration
Three month old APPV717I mice (C57BL/6 J back-
ground strain of the transgenic mice, with mutated
human APP-CT100 containing the London mutation
V717I) and C57BL/6 J mice (non-transgenic inbred
trains of mice, as normal control), both half male and
half female, were provided by the Institute of Experi-
mental Animals, Chinese Academy of Medical Sciences
& Peking Union Medical College (Beijing, China). All
animals were kept in the Pharmacological Experiment
Center of Dongzhimen Hospital, Beijing University of
Chinese Medicine, Beijing, PR China. They were main-
tained in a pathogen-free vivarium on a 12:12 h light:
dark cycle (12 h light: 0600 to 1800; 12 h dark: 1800 to
0600), temperature-controlled at 24 °C and has free
access to food and water. All experimental procedures
with animal were performed in accordance with the
National Institute of Health Guide for the Care and Use
of Laboratory Animals (NIH Publications No. 80-23)
revised in 1996 and had been approved by the Animal
Research Ethics Board of Beijing University of Chinese
Medicine.
Three-month-old male APPV717I transgenic mice were
randomly divided into ten groups (n = 12 per group) and
Fig. 1 Expression of CaMK II (Average OD) in hippocampal CA1 region in the experimental mice at the age of 7 months old were measured by
immunohistochemistry staining. Note:▲p < 0.05,vs control group, *p < 0.05,vs model group, ANOVA. CaMK II expression was determined by
immunohistochemistry in the hippocampus of experimental mice. Data are expressed as mean ± SD (Average OD) of the CaMK II positive
neuronal area (anti-body for CaMK II, 1:1000). Control: C57BL/6 J mice; APP: APPV717I mice; APP + D: donepezil; APP + Gl: GAPT low dose; APP +
Gm: GAPT middle dose; APP + Gh: GAPT high dose
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received intragastrically administrated vehicle or medi-
cines: APP group was given 0.5 % CMC, Donepezil group
was given donepezil (APP +D) (0.92 mg/kg/day i.g), and
low dose of GAPT (APP +Gl) (0.075 g/kg/day i.g), Middle
dose (APP + Gm) (0.15 g/kg/day i.g), and High dose
(APP + Gh) (0.30 g/kg/day i.g) for 8 or 4 months.
Three-month-old male C57BL/6 J mice as vehicle
control (n = 12) were given 0.5 % CMC for 8 or
4 months as well.
Immunohistochemistry and semi-quantitative analysis
All behaviorally-tested mice were deeply anesthetized by
10 % chloral hydrate (40 mg/kg body weight, i.p.), and
pericardially perfused with heparinized 0.9 % saline, then
removed the brain. The right hemisphere was immersion-
fixed in 4 % paraformaldehyde overnight at 4 °C and then
processed in phosphate buffered saline (PBS) solution
containing 30 % sucrose. Seven days later, brain samples
were embedded in paraffin. Serial coronal sections of the
hippocampus were cut at 35 μm intervals. One of every
three sections was selected and mounted onto slides for
immunohistochemical staining, while the left hemisphere
was snap frozen for Western blotting. Tissue from 12 rats
from each group was examined.
These brain sections were deparaffinised and de-
graded to distilled water, then unmasked the antigen
in 0.01 M Citrate Buffer with microwave, and
quenched endogenous peroxidise activity by 0.3 %
hydrogen peroxide in methanol for 20 min at 24 °C,
then blocked in 10 % antibodies in 3 % BSA/PBS for
30 min at 37 °C. After pouring off excess serum,
sections were incubated with the primary antibody in
humidified boxes at 4 °C overnight. Then, sections
were washed once again and incubated with biotin conju-
gated secondary antibodies (1:300, Fuzhou Maixin
Ltd., PR China) at 37 °C for 30 min, then washed
again and incubated with SABC for 1 h at 37 °C.
Subsequently, sections were stained by chromogen
3’3-diaminobenzidine tetrachloride (DAB). After that
sections were dehydrated, and affixed with coverslips.
All brain sections chosen for staining were on a
similar sagittal plane and contained approximately the
Fig. 2 Expression of CaN (Average OD) in hippocampal CA1 region in the experimental mice at the age of 7 months old were measured by
immunohistochemistry staining. Note: ▲p < 0.05,vs control group, ANOVA. CaN expression was determined by immunohistochemistry in the
hippocampus of experimental mice. Data are expressed as mean ± SD (Average OD) of the CaN positive neuronal area (anti-body for CaN, 1:100).
Control: C57BL/6 J mice; APP: APPV717I mice; APP + D: donepezil; APP + Gl: GAPT low dose; APP + Gm: GAPT middle dose; APP + Gh: GAPT high dose
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same area of hippocampus. The primary antibodies
used include CaMKII 1:1000 and CaN 1:100.
Average OD of each protein was measured in immu-
nostained sections, following the instructions of the
Image Pro Plus 6.0 software (Media CY Company, USA).
“Nonspecific” IHC staining in sections was chosen as
the control area for comparison with the immunoposi-
tive area in the neurons of the dentate gyrus. The exam-
iner was blinded to group assignment of the samples.
Western blotting
Western blots were performed as described previously
[43]. Briefly, the snap-frozen brain tissues cut from
hippocampus and cortex were weighted and homoge-
nized with a small pestle in ice with brain tissue lysis
buffer in the ratio of 1:10 (w/v) for 2 min and incubated
in ice for 30 min. The homogenate was centrifuged at
13,000 r.p.m. at 4 °C for 30 min, and the supernatant
was collected. Protein in the supernatant was mea-
sured by Bradford method with Coomassie Brilliant
Blue G-250. Loading buffer was added to samples in
the ratio of 4:1, after which they were placed in boiling
water for 5 min and then chilled immediately on ice; 10 μl
protein/well samples and 5 μl marker (10KD-170 KD)
were loaded onto a 10 % acrylamide gel and subjected to
SDS-PAGE by the Bio-Rad minigel system. Proteins were
then electro-blotted onto a polyvinylidine difluoride mem-
brane. The membrane was blocked by 5 % milk at 4 °C
overnight, then incubated with the primary antibody
(CaMKII 1:5000; CaN 1:4000). After three washes with
PBS containing 0.5 % Tween 20, the membrane was incu-
bated at room temperature for 1 h with HRP-conjugated
secondary antibody at 1:10000 dilution on the shaker.
After 3 times wash, blots were developed by the luminol
reagent (Pierce Biotechnology). Densitometric analysis of
the blots was completed using the Phoretix 1D software.
Statistical analysis
All data were analyzed with SPSS 19.0 software and
presented as the Mean ± SD. Comparison of different
treatments was evaluated by the Student's t test (two-
tailed). One-way ANOVA was used when comparisons
were made among three groups. P < 0.05 was considered
statistically significant.
Results
CaMKII and CaN expression levels in the experimental
mice at the age of 7 months old
Immunohistochemistry analysis showed significant
decrease of CaMKII in the CA1 region of 7 months
Fig. 3 Expression of CaMKII, CaN in hippocampus tissue homogenates of experimental mice at the age of 7 months were determined by
western-blotting. Notes: Control: C57BL/6 J mice; APP: APPV717I mice; APP + D: donepezil; APP + Gl: GAPT low dose; APP + Gm: GAPT middle dose;
APP + Gh: GAPT high dose. There was no significant difference between each group in both CaMKII, CaN
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old APPV717I transgenic mice (compare to control
group p < 0.05), while the CaMKII expression of
donepezil or GAPT treated transgenic mice were all
increased, and there was significant difference be-
tween GAPT low dose treated group and the model
group (P < 0.05). On the contrary, there was signifi-
cant increase of CaN in the brain cortex of 7 months
old APPV717I transgenic mice (compare to control
group p < 0.05), and the CaN expression of donepezil
or GAPT treated transgenic mice were all decreased,
but there were no significant difference between each
group (P > 0.05). Detailed data were shown in Figs. 1
and 2.
Western blot analysis showed that the similar
expression pattern of CaMKII and CaN in each group
as immunohistochemistry analysis showed, but there
was no significant difference between each group.
Detailed data were shown in Fig. 3.
CaMKII and CaN expression levels in the experimental
mice at the age of 11 months old
Immunohistochemistry analysis showed significant
decrease of CaMKII in the CA1 region of 11 months old
APPV717I transgenic mice (compare to control group
p < 0.01), while the CaMKII expression of donepezil
or GAPT treated transgenic mice were all significantly
increased (Donepezil vs. Model: P < 0.05; Gl vs.
Model: P < 0.01; Gm vs. Model: P < 0.01; Gh vs.
Model: P < 0.05), and the GAPT low dose treated
group had the highest CaMKII expression level. Detailed
data were shown in Fig. 4. There was significant increase
of CaN in the CA1 region of 11 months old APPV717I
transgenic mice (compare to control group p < 0.01), while
the CaN expression of donepezil or GAPT treated trans-
genic mice were all decreased, and there were significant
differences between donepezil or GAPT high dose treated
transgenic mice group and model group (Donepezil vs.
Fig. 4 Expression of CaMKII (Average OD) in hippocampal CA1 region in the experimental mice at the age of 11 months old were measured by
immunohistochemistry staining. Notes:▲p < 0.05, ▲▲p < 0.01,vs control group, *p < 0.05, **p < 0.01,vs model group, ANOVA. Control: C57BL/6 J
mice; APP: APPV717I mice; APP + D: donepezil; APP + Gl: GAPT low dose; APP + Gm: GAPT middle dose; APP + Gh: GAPT high dose. CaMKII
expression was determined by immunohistochemistry in the hippocampus of experimental mice. Data are expressed as mean ± SD (Average OD)
of the CaMKII positive neuronal area (anti-body for CaMKII, 1:1000)
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Model: P < 0.05;Gh vs. Model: P < 0.05), and the GAPT
high dose treated group had the lowest CaN expression
level. Detailed data were shown in Figs. 4 and 5.
Western blot analysis showed that the similar ex-
pression pattern of CaMKII and CaN in each group
as immunohistochemistry analysis showed, but there
was no significant difference in the expression of
CaMKII and CaN between each group. Detailed data
were shown in Fig. 6.
Discussion
APP/V717I transgenic mice used in this study were of
the C57BL/6 J genetic background and carrying mutated
human APP-CT100 containing the London mutation
V717I, which is characterized by the increased gener-
ation of Aβ42 and AD-like pathological changes [46].
However, the formation of amyloid plaques in the mice
only initiates around their 9 months old [47, 48], and
which is preceded by earlier phenotypic changes that
comprise impaired LTP and cognitive defects as early
as age 4–6 months [49]. These findings indicate the
critical involvement of amyloid peptides in defective
LTP of APP transgenic mice. But the mechanisms
behind the defective LTP in this transgenic mouse are
still not clear. Especially, the expression of CaMKII
and CaN in the brain of this transgenic mouse are
not well investigated. In order to observe levels of
CaMKII and CaN before and after amyloid plaques
formation, as well as to reveal whether the cognitive
improving effects of GAPT is conducted through
rebalance CaMKII and CaN, APPV717I transgenic
mice aged 3 months were used in our experiment
and treated with GAPT up to their 7 or 11 months.
That is 3 months old APPV717I transgenic mice were
treated by GAPT extracts for 4 months or 8 months
in this study.
Fig. 5 Expression of CaN (Average OD) in hippocampal CA1 region in the experimental mice at the age of 11 months old were measured by
immunohistochemistry staining. Notes:▲P < 0.05, ▲▲P < 0.01, vs Control group, *P < 0.05,vs model group, ANOVA. Control: C57BL/6 J mice; APP:
APPV717I mice; APP + D: donepezil; APP + Gl: GAPT low dose; APP + Gm: GAPT middle dose; APP + Gh: GAPT high dose. CaN expression was
determined by immunohistochemistry in the hippocampus of experimental mice. Data are expressed as mean ± SD (Average OD) of the CaN
positive neuronal area (anti-body for CaN, 1:100)
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GAPT, also called GEPT in our previous papers, is a
combination of eight herbal extracts. It has showed
marked enhancement to the function of learning and
memory of AD rat model induced by Aβ1-42peptide, as
well as APPV717I transgenic mice during the 8 months’
treatment [43, 44]. It's reduction of endogenous Aβ
peptide in the brain of APPV717I transgenic mice may
conducted via the inhibition of PS1 activity rather than
BACE1, as well as the promotion of insulin-degrading
enzyme (IDE) and neprilysin activity [43]. And previous
preliminary clinical study also indicated that a three
month treatment of GAPT had significant effectiveness
in improving memory and cognitive impairment and
delaying memory decline through one year in 70
patients with aMCI [50]. However, it is unknown for
mechanisms behind synaptic protection effects of
GAPT in APPV717I transgenic mice. Spatial learning
and memory ability of all mice were measured by
Orientation Navigation Tests and Spatial Probe Tests
with Morris Water Maze (MWM), which found that
GAPT significantly improve the spatial learning and
memory of APPV717I transgenic mice during the
8 months’ treatment (detailed data will be published
in another article).
Immunohistochemistry analysis showed that there
were significant decrease of CaMKII expression in the
CA1 region of APPV717I transgenic mice, while the
CaMKII expression of donepezil or GAPT treated trans-
genic mice were increased. Although there was only
significant difference between GAPT low dose treated
group and the model group in 7 months old mice, there
were significant differences between each treated group
and the model group in 11 months old mice, and the
GAPT low dose treated group had the highest CaMKII
expression level. Thus, the CaMKII expression is
gradually decreased in the brain of APPV717I transgenic
mice, and the increase effects of donepezil or GAPT on
CaMKII expression is time-dependent. The longer treat-
ment the better increase effects.
Immunohistochemistry analysis showed significant
increase of CaN in the brain cortex of APPV717I
transgenic mice, and there were decrease in CaN expres-
sion in donepezil or GAPT treated transgenic group.
However, there were only significant differences between
donepezil or GAPT high dose treated transgenic mice
group and model group in 11 months old mice, and the
GAPT high dose treated group had the lowest CaN
expression level. The present result shows that the CaN
expression is gradually increased in the brain of
APPV717I transgenic mice,and the decrease effects of
donepezil or GAPT on CaMKII expression is also time-
dependent.
These results were consistent with others researches.
For example, it has been shown that there was reduced
Fig. 6 Expression of CaMKII, CaN in hippocampus tissue homogenates of experimental mice at the age of 11 months were determined
by western-blotting. Notes: Control: C57BL/6 J mice; APP: APPV717I mice; D: donepezil; Gl: GAPT low dose; APP + Gm: GAPT middle dose;
APP + Gh: GAPT high dose. There was no significant difference in the expression of CaMKII and CaN between each group
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p-CaMKII level in specific brain regions in AD patients,
such as frontal cortex and hippocampus [51] and there
were decreased CaMKII activation and increased CaN
levels in a short-term memory and E-LTP deficits rat
model induced by beta amyloid and stress [52]. These
kinds of changes also have been shown to contribute to
the inhibition of LTP in CA1 region or dentate gyrus of
rat hippocampus by acute application of synthetic beta
amyloid. And such inhibition of LTP can be blocked by
specific inhibitors of CaN [53, 54].
Western blot analysis showed the similar expression
pattern of CaMKII and CaN in each group in 7 or
11 months old mice as immunohistochemistry analysis
showed, but there was no significant difference between
each group. This may partially because there are differ-
ent expression levels of CaMKII and CaN in different
cells, and there are different status of those two proteins,
active or inactive. For example, there are evidences
suggest that Aβ induces different changes of CaN
expression in neurons and astrocytes, and CaN A, the
catalytic subunit of CaN, is proteolytically activated in
AD cortex by the degradation of an autoinhibitory
domain [39, 40] and which is expressed in reactive astro-
cytes surrounding senile plaques [41]. As far as CaMKII
expression is concerned, very early research has found
no alteration of CaMKII expression in the AD brain
[55], and only recent research has found phosphorylated
CaMKII expression was reduced in the frontal cortex and
hippocampus of AD brains [51]. Therefore, further studies
about specific status of those two proteins in certain brain
cells of the APPV717I transgenic mice are needed.
However, these data is fully valid to indicate that
GAPT extract may balance the expression of CaMKII
and CaN in the brain of APPV717I transgenic mice.
And different doses of GAPT may have slight difference
in the influence of those two proteins. That is, high dose
GAPT have potentially higher CaN inhibiting effects,
while low dose may have higher CaMKII activating ef-
fects in APP mice. And all these effects can be exerted
before the formation of amyloid plaques. This may par-
tially explain the A 24-week preliminary study of GAPT
showed a significant improvement on cognitive function
in patients with aMCI, an early stage of AD [45, 56].
Conclusion
There were obvious disturbance of CaMKII and CaN
expression in the CA1 region of APPV717I transgenic
mice either before or after the formation of amyloid
plaques. While, GAPT extract have significant effect-
iveness in restoring the balance of CaMKII and CaN,
that is activating the expression of CaMKII and
inhibiting the expression of CaN. This may partially
explain the cognitive improving effects of GAPT in
APPV717I transgenic mice.
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